Fig. 3
From: Humoral immune response after different SARS-CoV-2 vaccination regimens
Development of SARS-CoV-2 neutralising antibodies (VNA) after first (empty circles) and second (filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell-based virus-neutralisation test (cVNT) using the SARS-CoV-2 variant of concern B.1.1.7 (alpha) strain (B) were applied to measure the VNAs. The assay cut-offs are indicated by dashed lines. The median and the 95% confidence interval were calculated for each group in A and B. Ns non-significant; *p < 0.05; ***p < 0.001; ****p < 0.0001 (Kruskal-Wallis test)